ScreenerHero

AKTS Aktis Oncology, Inc.

NAS · US · Healthcare · Biotechnology · aktisoncology.com
18.00USD+0.78%Mkt Cap: 1.00B $P/E: —

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.00B USD
Enterprise Value487.28M USD
Revenue (TTM)10.06M USD
Gross Profit-68.22M USD
Net Income (TTM)-63.73M USD
Revenue/Share0.38 USD
Last Price18.00 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees79
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.32
PEG—
EV/EBITDA-5.78
EV/Revenue48.44
P/S98.74
P/B2.04
EPS (TTM)-1.70
EPS (Forward)-2.15
52W Range
14.7217% of range34.19
52W High34.19 USD
52W Low14.72 USD
Profitability
Gross Margin0.00%
Oper. Margin-853.99%
EBITDA Margin0.00%
Profit Margin-980.93%
ROE43.61%
ROA-24.06%
Growth
Revenue Growth111.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.13M USD
CapEx (TTM)9.58M USD
FCF Margin—
FCF Yield—
Net Debt-506.08M USD
Net Debt/EBITDA6.00
Balance Sheet
Debt/Equity-0.08
Current Ratio16.33
Quick Ratio16.17
Book Value/Sh8.76 USD
Cash/Share9.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.39 USD
Upside (mean)+96.6%
Target Range31.50 USD – 40.00 USD
31.50+96.6% to mean40.00
# Analysts9
Ownership
Shares Out.53.75M
Float28.59M
Insiders14.05%
Institutions72.94%
Short Interest
Short Ratio10.9d
Short % Float20.12%
Short % Out.5.85%
Shares Short3.25M
Short (prev mo.)3.45M
Technical
SMA 5023.27 (-22.7%)
SMA 20021.48 (-16.2%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)436.68K
Avg Vol (10d)341.62K
Technical Indicators
RSI (14)25.4
MACD-1.6418
MACD Signal-1.4403
MACD Hist.-0.2014
BB Upper24.64 USD
BB Middle20.63 USD
BB Lower16.61 USD
BB Width38.91%
ATR (14)1.153 USD
Vol Ratio (20d)0.56x